Tag:

Astellas

Latest Headlines

Latest Headlines

Xtandi marketer Astellas scrums with rugby partners for prostate cancer awareness

Astellas is partnering with both USA Rugby and the Australia Rugby Union for a new prostate cancer campaign. Though it's an unbranded push, the "Pass4Prostate" promotion fits right in with Astellas' stepped-up marketing of Xtandi, the prostate cancer med now approved for previously untreated patients.

Astellas, Medivation to amp up unbranded Xtandi marketing for pre-chemo use

Astellas and Medivation haven't been marketing Xtandi much for the pre-chemotherapy indication in prostate cancer it won last fall. Begun two months ago, the direct-to-consumer efforts--mostly in print--has appeared in journals such as  Patient Resourc e; it also includes some direct relationship marketing.

Astellas wagers $760M to launch an autoimmune biotech in Cambridge, MA

Japanese drugmaker Astellas is teaming up with a Swiss biotech to launch a joint venture focused on autoimmune disease, promising up to $760 million with an option to buy the new company outright.

Medivation's Xtandi sales fell short in Q1, but analysts say it's gaining on J&J's Zytiga

Astellas and Medivation may have disappointed analysts with their first-quarter Xtandi sales. But recent script numbers suggest the disappointment may be short-lived--and that the prostate cancer pill may be gaining ground on its head-to-head rival, Johnson & Johnson's Zytiga.

Astellas dives into immuno-oncology with a sweeping biotech deal

Japanese pharma giant Astellas is entering the booming field of immuno-oncology, pairing up with Cambridge, MA's Potenza Therapeutics to work on a wide variety of treatments that use the body's natural defenses to combat cancer.

Japan's Astellas, U.K.'s Potenza in immuno-oncology development deal

Japan's Astellas Pharma and U.K.-based biotech Potenza Therapeutics announced a R&D effort into immuno-oncology therapies centered on checkpoint pathways, co-stimulatory signals and regulatory T cells that could lead to a buyout.

Roche's Ventana strikes companion diagnostic deal with Astellas Pharma

Roche's Ventana Medical Systems announced a companion diagnostic agreement centered around Astellas Pharma's cancer fighting ASP5878.

Astellas options global R&D rights to University of Texas leukemia candidate

Astellas Pharma has optioned the rights to be the first to negotiate global exclusive research-and-develop rights for a leukemia drug the University of Texas is set to test in early-stage trials in the United States. In return, Astellas is to provide $26 million in funding through two Phase I stages.

Amgen link strong as Astellas files with PMDA on Evolocumab, and new indication for Kiklin

Japan's Astellas Pharma has filed with Japan's Pharmaceutical and Medical Devices Agency for approval of PCSK9 inhibitor evolocumab for high cholesterol under the Amgen Astellas BioPharma joint venture.

Astellas scores FDA approval for life-threatening fungus-fighter

The FDA offers incentives for developing products that target life-threatening infections, and Astellas just became the latest drugmaker to take advantage.